N/A N=9 Hair Loss Prevention Study for Pancreatic Cancer
Alopecia
Primary: Hair Preservation — 2; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=109 Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis
Moderate-to-Severe Atopic Dermatitis
Primary: Nemolizumab Serum Concentrations — 5950; 2900; 3080; 5150 nanograms per milliliters (ng/mL)
Phase 1 N=6 A Study of LY3502970 in Healthy Male Participants
Healthy
Primary: Feces Excretion of LY3502970 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered — 86.75 percentage of the total radioactive dose
Phase 2 N=46 Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · Acute Leukemia
Primary: Median Time in Days to Onset of Grade II-IV aGVHD by Day 100 After Study Treatment — 34 days
Phase 2 N=79 Trial of Neoadjuvant Therapy With Paclitaxel and Carboplatin in Operable Locally Advanced Head and Neck Cancer Patients
Head and Neck Squamous Cell Carcinoma
Primary: Major Pathologic Response — 22 Participants
Phase 1 N=27 A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Orforglipron — 89.9; 79.1 nanogram*hour per milliliter
Phase 2 N=61 CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone
Prostate Cancer
Primary: Prostate-Specific Antigen (PSA) or Radiographic Progression — 10 participants
Phase 2 N=53 Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy
Prostate Adenocarcinoma · Stage IIB Prostate Cancer AJCC v8 · Stage III Prostate Cancer AJCC v8
Primary: Freedom From Failure (FFF) — 7; 16; 5 Participants
N/A N=440 VR Smoking Cessation During a Dental Hygiene Visit
Smoking Cessation
Primary: Use of Any Evidence-Based Treatment (EBT) for Smoking Cessation — 75; 49; 76; 49 Participants
Phase 1 N=32 A Drug Interaction Study of Cyclosporine and LY3502970 in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3502970 — 332; 857 nanogram * hour per milliliter (ng*hr/mL
Phase 1 N=68 A Study of LY3502970 in Participants With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug — 1; 0; 0; 0 Participants
Phase 3 N=509 Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema
Diabetic Macular Edema
Primary: Best Corrected Visual Acuity — 4.89; 5.55; 7.09; 7.71 Letters
Phase 4 N=37 Cannabidiol for Bilateral Total Knee Arthroplasty
Pain, Postoperative · Opioid Use · Knee Osteoarthritis
Primary: Cumulative Opioid Usage in First 72 Hours Postoperatively — 209.0; 144.0; 203.2 Morphine Milligram Equivalents (MME)
Phase 1 N=72 A Study of LY3502970 in Healthy Overweight and Obese Participants
Healthy · Obese
Primary: Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to…
N/A N=191 Population Based Lighting Study on Older Adults
Lightning Strategies on Health · Circadian Rhythms Photoentrainment · Photoentrainment and Sleep
Primary: Change in Pittsburgh Sleep Quality Index (PSQI) — 0; 0 Score change — p=0.14